Welcome to our dedicated page for Trinity Biotech news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech stock.
Trinity Biotech plc reports developments across its commercial-stage diagnostics and health technology business, including clinical laboratory products, point-of-care testing, diabetes management solutions, and wearable biosensor development. Its updates frequently cover the Premier Hb9210 HbA1c laboratory blood glucose monitoring platform, TrinScreen HIV testing, and the CGM+ continuous glucose monitoring program.
Company news also addresses specialty diagnostics initiatives such as EpiCapture prostate cancer testing and autoimmune biomarker work supported by its New York State Department of Health-certified reference laboratory. Other recurring topics include commercial operations in North America, manufacturing and cost-control actions under its Comprehensive Transformation Plan, ADS-based financing arrangements, trading updates, and Nasdaq listing-status notices.
Trinity Biotech (NASDAQ:TRIB) launched Trinovium, a subsidiary focused on advanced liquid cooling fluids and intelligence systems for AI and high‑performance computing data centers.
Trinovium targets the data center liquid cooling market, projected to grow from $4 billion in 2026 to $27 billion by 2033 (31.5% CAGR), leveraging Trinity’s US/EU high‑purity fluid manufacturing and analytics. Initial products include a direct‑to‑chip coolant built around ultra‑high purity, corrosion protection, and healthcare‑grade consistency, plus a planned fluid health monitoring platform. Trinity continues to commercialize its FDA 510(k)‑cleared diabetes and hemoglobin analyzers, WHO‑prequalified HIV tests, and develop its CGM+ continuous glucose monitoring solution.
Trinity Biotech (Nasdaq: TRIB) received additional purchase orders for over 2 million TrinScreen HIV tests, scheduled for Q3 2026 fulfillment and expected to support 2026 revenue and profitability targets.
Q1 2026 revenue rose 43% to $10.8m, with gross margin improving from 25.2% to 35.4%. Net loss narrowed to $4.4m, and adjusted EBITDA was negative $1.1m. Rapid HIV sales reached $3.7m, including $2.3m from TrinScreen HIV, while haemoglobin product sales increased to $3.3m. Outsourced manufacturing scale-up for UniGold HIV and TrinScreen HIV is part of the Comprehensive Transformation Plan, aimed at further improving margins and cash generation.
Trinity Biotech (NASDAQ: TRIB) appointed Jerry Lydon as Head of North America Commercial Operations on May 1, 2026, to lead commercial execution and support revenue quality and profitability as the company shifts from transformation execution to extracting operating leverage.
Q4 2025 revenue was $11.1m; full‑year 2025 revenue was $43.8m. Gross margin improved ~400 bps year and quarter, adjusted EBITDA narrowed versus prior year, and one‑off IFRS charge of $10.0m affected net loss.
Trinity Biotech (Nasdaq: TRIB) reported successful clinical results for an enhanced EpiCapture™ urine-based prostate cancer test on March 23, 2026. The upgraded test uses machine learning with added patient features, including ethnicity, and showed an AUC of 85% in a study of ~750 diverse samples. Trinity plans to commercialize EpiCapture as a Laboratory Developed Test through its New York reference laboratory and will submit the data for peer-reviewed publication.
Trinity Biotech (Nasdaq: TRIB) entered a collaboration with the University at Buffalo to co-develop and commercialize a proprietary suite of biomarkers for earlier, more accurate detection of Sjögren’s Syndrome.
The agreement leverages biomarkers licensed to Trinity subsidiary IMMCO, UB CAT funding support, and Trinity’s NYSDOH-approved reference laboratory as the U.S. launch platform.
Trinity Biotech (Nasdaq: TRIB) announced it has begun commercial rollout in Brazil of its upgraded Premier Hb9210™ HbA1c column system following local regulatory approval on March 12, 2026.
The Premier Hb9210™ is the only HbA1c system awarded IFCC Gold for 2026. Trinity also appointed Bruna Gigliotti to lead its Brazilian commercial organisation to support market adoption.
Trinity Biotech (Nasdaq: TRIB) will attend ATTD 2026 in Barcelona to accelerate partnerships and commercialization planning for its next‑generation CGM platform, CGM+. Recent clinical performance supported the decision to advance the program into a pivotal clinical trial in 2026, with results indicating the system can meet modern CGM accuracy standards.
Executives will engage prospective collaborators across clinical research, technology integration, and commercial distribution ahead of the pivotal trial.
Trinity Biotech (Nasdaq: TRIB) announced technical breakthroughs advancing its next-generation, finger‑stick calibration‑free CGM system, CGM+, reporting >650 days of clinical testing data and a material reduction in MARD across multi-day wear. The company expects to initiate a pivotal clinical trial in 2026 and highlights a modular, AI-native, multimodal device design aimed at lower cost and improved sustainability versus current CGMs.
The release cites needle-free insertion advances, multimodal sensing for personalized metabolic insights, and market opportunity context (global CGM ~$15.3B projected 2026).
Trinity Biotech (Nasdaq: TRIB) provided a Q4 2025 trading update and business progress report. The company expects Q4 2025 revenue of $11.5M–$12.5M, down from $15.9M in Q4 2024, driven by HIV testing market disruptions and manufacturing transitions.
Key developments include February 2026 local approval to outsource Uni-Gold manufacturing, continued commercial traction for Uni-Gold and TrinScreen, IFCC Gold classification for its HbA1c solution, and ongoing pipeline work on CGM+, EpiCapture, and PrePsia.
Trinity Biotech (Nasdaq: TRIB) entered a $25 million Standby Equity Purchase Agreement (SEPA) with a Yorkville affiliate dated Feb 25, 2026 to provide up to 36 months of discretionary funding. The facility permits sales of ADSs at discounts of 97% (3-day VWAP) or 95% (1-day VWAP), subject to resale registration, trading-volume caps and a 4.99% Yorkville ownership limit. Trinity reported $48.6 million revenue for the 12 months ended Sept 30, 2025 and cited strengthened HIV testing sales and later-stage progress on its CGM+ needle-free glucose sensor following August 2025 trial results.